Teva to expand production in Gödöllő
Israeli generic drug maker Teva will soon complete construction of a new production hall at its plant in Gödöllő, just outside Budapest, as part of an almost HUF 30bn investment, daily Világgazdaság said on Monday, quoting communications chief Peter Paplanos.
The plant will start producing the active ingredient for the cancer drug 5-fluorouracil next year, the paper said.
Then paper notes that several hospitals in Hungary have run out of 5-fluorouracil recently. Antal Feller, CEO of pharmaceutical wholesaler Hungaropharma, said there is a shortage of the product across Europe as the plant making the drug in the Netherlands has been temporarily shut down due to a technological problem.
TEVA announced a €65m expansion at the Gödöllő plant in January 2010. The drug maker said the project, to be completed by the end of 2014, will mainly affect the production of cancer drugs, eye drops and injections. The first phase of the project was to be completed by 2011.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.